Induction of histone crotonylation with bromodomain-containing protein 4 (BRD4) inhibitors can inhibit the proliferation and migration of prostate cancer cells, suggesting histone crotonylation can serve as biomarker for the diagnosis of prostate cancer and a therapeutic target for the treatment (Xu et al., 2021). Here, BRD4 is linked to prostate carcinoma.